Morgan Stanley Upgrades Relypsa, Inc. (RLYP) to Equalweight

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. DAL
9. TMUS
10. VZ

Go back to Morgan Stanley Upgrades Relypsa, Inc. (RLYP) to Equalweight

Cantor Fitzgerald Downgrades Relypsa, Inc. (RLYP) to Hold

July 26, 2016 7:38 AM EDT

Cantor Fitzgerald downgraded Relypsa, Inc. (NASDAQ: RLYP) from Buy to Hold with a price target of $32.00 (from $41.00).

For an analyst ratings summary and ratings history on Relypsa, Inc. click here. For more ratings news on Relypsa, Inc. click here.

Shares of Relypsa, Inc. closed at $31.97 yesterday.

... More

Galenica to Acquire Relypsa (RLYP) for $32/Share

July 21, 2016 5:42 AM EDT

Galenica Group and Relypsa, Inc. (Nasdaq: RLYP) announced that the companies have entered into a definitive agreement under which Galenica will acquire Relypsa. This transaction further strengthens Galenicas Business unit, Vifor Pharma, as the company will gain full global rights to the potassium binder Veltassa (patiromer) for oral suspension and enhance its growing position as a global specialty pharmaceutical company. Under the terms of the merger agreement, Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Through this acquisition, Vifor Pharma will gain a fully-integrated commercial organization in the United... More